Live Breaking News & Updates on Wuerzburg the university

Stay informed with the latest breaking news from Wuerzburg the university on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Wuerzburg the university and stay connected to the pulse of your community

Aeterna Zentaris Announces Exclusive License Agreement and

- Company secures next step to continue to build-out pipeline of assets - Company exercised its option to enter into an exclusive license of...

China , Germany , United-states , United-kingdom , Israel , Hubei , Guangdong , Wuhan , Canada , Palestinian , Canadian , Jenene-thomas

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

China , Germany , United-states , United-kingdom , Israel , Hubei , Guangdong , Wuhan , Canada , Palestinian , Canadian , Jenene-thomas

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with ...

Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with ...
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

China , Germany , United-states , United-kingdom , Israel , Hubei , Guangdong , Wuhan , Canada , Palestinian , Canadian , Jenene-thomas

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics
January 28, 2021 08:05 ET
| Source:
Aeterna Zentaris Inc
Aeterna Zentaris Inc
Montreal CANADA
- Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of
neuromyelitis optica spectrum disorder
- Initial step in growth strategy to build-out pipeline of assets
- Aeterna Zentaris to develop potential therapeutic treatment option for neuromyelitis optica spectrum disorder (“NMOSD”), an orphan indication with strong unmet medical need and significant market opportunity
CHARLESTON, S.C., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has licensed the exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific, autoimmunity modifying proteins (“AIM Biologicals”) for the potential treatment of neuromyelitis optica spectrum disorder (“NMOSD”) from the Julius-Maximilians-University Wuerzburg (the “University”).

United-states , Germany , Canada , United-kingdom , Israel , Palestinian , Canadian , Jenene-thomas , Aeterna-zentaris-gmb , Joerg-wischhusen , Klaus-paulini , Valentin-bruttel

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

Article content
– Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of
neuromyelitis optica spectrum disorder
– Initial step in growth strategy to build-out pipeline of assets
– Aeterna Zentaris to develop potential therapeutic treatment option for neuromyelitis optica spectrum disorder (“NMOSD”), an orphan indication with strong unmet medical need and significant market opportunity
CHARLESTON, S.C., Jan. 28, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has licensed the exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific, autoimmunity modifying proteins (“AIM Biologicals”) for the potential treatment of neuromyelitis optica spectrum disorder (“NMOSD”) from the Julius-Maximilians-University Wuerzburg (the “University”).

United-states , Germany , Canada , United-kingdom , Israel , Palestinian , Canadian , Jenene-thomas , Aeterna-zentaris-gmb , Joerg-wischhusen , Klaus-paulini , Valentin-bruttel

Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic ...
Aeterna Zentaris IncFebruary 2, 2021 GMT
- Company secures next step to continue to build-out pipeline of assets
- University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19
- Aeterna Zentaris to evaluate the University’s coronavirus vaccine platform technology including COVID-19 under an exclusive option agreement
CHARLESTON, S.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has entered into an exclusive option agreement to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities. The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine.

Wuhan , Hubei , China , Germany , United-states , United-kingdom , Israel , Guangdong , Canada , Palestinian , Canadian , German